Pembrolizumab May Be More Effective, Safer Than Ipilimumab for Advanced Melanoma

Share this content:
Pembrolizumab better prolonged progression-free survival and overall survival than did ipilimumab in advanced melanoma.
Pembrolizumab better prolonged progression-free survival and overall survival than did ipilimumab in advanced melanoma.

Pembrolizumab, an anti-PD-1 antibody, prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma, a recent study published online in The New England Journal of Medicine has shown.

For this controlled, phase III study, researchers enrolled 834 patients with advanced melanoma and randomly assigned them 1:1:1 to receive pembrolizumab 10mg/kg every 2 weeks, pembrolizumab 10mg/kg every 3 weeks, or ipilimumab 3mg/kg every 3 weeks for four doses.

Results showed that the estimated progression-free survival rates were 47.3%, 46.4%, and 26.5% for pembrolizumab every 2 weeks, pembrolizumab every 3 weeks, and ipilimumab, respectively (HR = 0.58; < 0.001 for both pembrolizumab regimens versus ipilimumab; 95% CI: 0.46-0.72 and 0.47-0.72, respectively).

Researchers found that estimated 1-year survival rates were 74.1% for pembrolizumab every 2 weeks, 68.4% for pembrolizumab every 3 weeks, and 58.2% for ipilimumab (HR for pembrolizumab every 2 weeks = 0.63; 95% CI: 0.47-0.83; P = 0.0005; HR for pembrolizumab every 3 weeks = 0.69; 95% CI: 0.52-0.90; = 0.0036).

RELATED: Nivolumab, Ipilimumab More Effective Than Ipilimumab Alone for Melanoma

The study also showed improved response rates with pembrolizumab (every 2 weeks = 33.7%, every 3 weeks = 32.9%) compared with ipilimumab (11.9%) (P < 0.001 for both comparisons).

In regard to safety, 13.3% and 10.1% of those who received pembrolizumab every 2 weeks and every 3 weeks, respectively, experienced grade 3 to 5 treatment-related adverse events compared with 19.9% in the ipilimumab group.

Ipilimumab is currently the standard-of-care treatment for patients with advanced melanoma.

Reference

  1. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015. [Epub ahead of print]. doi: 10.1056/NEJMoa1503093.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters